GB0423950D0 - Pharmaceutical composition containing botulinum neurotoxin - Google Patents

Pharmaceutical composition containing botulinum neurotoxin

Info

Publication number
GB0423950D0
GB0423950D0 GBGB0423950.5A GB0423950A GB0423950D0 GB 0423950 D0 GB0423950 D0 GB 0423950D0 GB 0423950 A GB0423950 A GB 0423950A GB 0423950 D0 GB0423950 D0 GB 0423950D0
Authority
GB
United Kingdom
Prior art keywords
pharmaceutical composition
composition containing
botulinum neurotoxin
containing botulinum
neurotoxin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GBGB0423950.5A
Other versions
GB2426702A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ipsen Ltd
Original Assignee
Ipsen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Ltd filed Critical Ipsen Ltd
Priority to GB0423950A priority Critical patent/GB2426702A/en
Publication of GB0423950D0 publication Critical patent/GB0423950D0/en
Priority to US11/659,449 priority patent/US20080102090A1/en
Priority to ES05767945.8T priority patent/ES2526913T3/en
Priority to EP05767945.8A priority patent/EP1778279B1/en
Priority to PCT/GB2005/003057 priority patent/WO2006013370A1/en
Publication of GB2426702A publication Critical patent/GB2426702A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893Botulinum neurotoxin (3.4.24.69)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
    • A61K2201/06
GB0423950A 2004-08-04 2004-10-28 Pharmaceutical composition comprising botulinum neurotoxin Withdrawn GB2426702A (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
GB0423950A GB2426702A (en) 2004-10-28 2004-10-28 Pharmaceutical composition comprising botulinum neurotoxin
US11/659,449 US20080102090A1 (en) 2004-08-04 2005-08-03 Pharmaceutical Compositon Containing Botulinum Neurotoxin A2
ES05767945.8T ES2526913T3 (en) 2004-08-04 2005-08-03 Pharmaceutical composition containing botulinum neurotoxin 2
EP05767945.8A EP1778279B1 (en) 2004-08-04 2005-08-03 Pharmaceutical composition containing botulinum neurotoxin a2
PCT/GB2005/003057 WO2006013370A1 (en) 2004-08-04 2005-08-03 Pharmaceutical composition containing botulinum neurotoxin a2

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0423950A GB2426702A (en) 2004-10-28 2004-10-28 Pharmaceutical composition comprising botulinum neurotoxin

Publications (2)

Publication Number Publication Date
GB0423950D0 true GB0423950D0 (en) 2004-12-01
GB2426702A GB2426702A (en) 2006-12-06

Family

ID=33515710

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0423950A Withdrawn GB2426702A (en) 2004-08-04 2004-10-28 Pharmaceutical composition comprising botulinum neurotoxin

Country Status (1)

Country Link
GB (1) GB2426702A (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2072039A1 (en) * 2007-12-21 2009-06-24 Merz Pharma GmbH & Co.KGaA Use of a neurotoxic component of Clostridium botulinum toxin complex to reduce or prevent side effects
EP3612154A4 (en) * 2017-04-20 2020-12-16 Bonti, Inc. Botulinum neurotoxins for treating hyperhidrosis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030095927A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating muscular and skeletal disorders
JP2002501033A (en) * 1998-01-26 2002-01-15 ユニバーシティー オブ マサチューセッツ Biologically active hemagglutinin of Clostridium botulinum type A and its use
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US20040033241A1 (en) * 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
AU2002320127A1 (en) * 2001-06-21 2003-01-08 Surromed, Inc. Covalent coupling of botulinum toxin with polyethylene glycol

Also Published As

Publication number Publication date
GB2426702A (en) 2006-12-06

Similar Documents

Publication Publication Date Title
IL180380A0 (en) Pharmaceutical composition containing botulinum neurotoxin
PT1776137E (en) Pharmaceutical composition containing botulinum neurotoxin a2
IL225848A0 (en) Therapeutic composition with a botulinum neurotoxin
IL177480A0 (en) Pharmaceutical composition
ZA200606154B (en) Pharmaceutical composition comprising pimobendan
EP1871347A4 (en) Pharmaceutical composition
EP1937255A4 (en) Pharmaceutical composition
EP1862184A4 (en) Pharmaceutical composition
EP1889613A4 (en) Pharmaceutical composition comprising vitamin k
HU0401177D0 (en) Pharmaceutical composition
GB0423952D0 (en) Pharmaceutical composition containing botulinum neurotoxin
GB0417367D0 (en) Pharmaceutical composition containing botulinum neurotoxin
GB2411355B (en) Pharmaceutical composition
GB0423953D0 (en) Pharmaceutical composition containing botulinum neurotoxin
ZA200701932B (en) Pharmaceutical composition
GB0425255D0 (en) Pharmaceutical composition
GB0423950D0 (en) Pharmaceutical composition containing botulinum neurotoxin
GB0421288D0 (en) Pharmaceutical composition containing botulinum neurotoxin
ZA200701931B (en) Pharmaceutical composition
HUP0500813A2 (en) Pharmaceutical composition containing violaceae extract
GB0421290D0 (en) Pharmaceutical composition containing botulinum neurotoxin
HK1216998A1 (en) Pharmaceutical compositions comprising botulinum neurotoxin
HUP0401176A2 (en) Pharmaceutical composition having prpkinetic effect
ZA200808768B (en) Pharmaceutical composition containing the NMB0606 protein
ZA200805355B (en) Pharmaceutical compositions containing protein NMA0939

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)